Key result
Intravenous administration of antithrombin III prevented lipopolysaccharide-induced pulmonary accumulation of leukocytes and increased vascular permeability in rats by promoting prostacyclin release.
Why the study?
Does intravenous antithrombin III prevent endotoxin-induced pulmonary vascular injury in rats?
Does intravenous antithrombin III prevent endotoxin-induced pulmonary vascular injury in rats?
Antithrombin III attenuates endotoxin-induced pulmonary vascular injury in rats by promoting the release of prostacyclin from endothelial cells.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating in rodent endotoxin lung injury; human trials needed before any clinical consideration.
Uchiba et al. (1996) studied Endotoxin-induced pulmonary vascular injury. Antithrombin III (AT III) was evaluated on Pulmonary accumulation of leukocytes and increase in pulmonary vascular permeability. Intravenous administration of antithrombin III prevented lipopolysaccharide-induced pulmonary accumulation of leukocytes and increased vascular permeability in rats by promoting prostacyclin release.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: